Akèy › Leksemi mieloïd egi › Kansas › Overland Park
Etid klinik pou Leksemi mieloïd egi nan Overland Park, KS
11 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Overland Park (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi lwen
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi lwen
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Clinical Research Center, Fairway · 3 mi lwen
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi lwen
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi lwen
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Ap rekriteFaz 3
- US-Kansas City KS-KUMC, Fairway · 3 mi lwen
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Ap rekriteFaz 1
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi lwen
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- The University of Kansas Medical Center Research Institute, Fairway · 3 mi lwen
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Ap rekriteFaz 1
- University of Kansas, Fairway · 3 mi lwen
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Ap rekriteFaz 2
- University of Kansas Cancer Center, Fairway · 3 mi lwen
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Ap rekriteFaz 1
- University of Kansas Cancer Center, Fairway · 3 mi lwen
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Overland Park
- Kansè Poumon ki pa ti selil16 etid
- Kansè poumon11 etid
- Kansè nan tete10 etid
- Fibrilasyon atriyal8 etid
- Kansè kolorektal8 etid
- Obèsite7 etid
- Kansè pankreyas7 etid
- Kansè pwostat7 etid
- Melanom6 etid
- Sipwa6 etid
- Kansè ovè6 etid
- Kansè (tout kalite)5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.